BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND GNA11, GNA-11, 2767, ENSG00000088256 AND Treatment
10 results:

  • 1. Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.
    Colombo D; Gatti L; Sjöstrand L; Carenini N; Costantino M; Corna E; Arrighetti N; Zuccolo M; De Cesare M; Linder S; D'Arcy P; Perego P
    Biochem Pharmacol; 2022 Mar; 197():114900. PubMed ID: 34995485
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.
    Brown ZJ; Labiner HE; Shen C; Ejaz A; Pawlik TM; Cloyd JM
    J Surg Oncol; 2022 Feb; 125(2):185-193. PubMed ID: 34599756
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data.
    Lu X; Lu J; Liao B; Li X; Qian X; Li K
    Sci Rep; 2017 Nov; 7(1):16188. PubMed ID: 29170526
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
    Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
    Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.
    Corno C; Gatti L; Arrighetti N; Carenini N; Zaffaroni N; Lanzi C; Perego P
    Biochem Pharmacol; 2017 Jul; 136():40-50. PubMed ID: 28404378
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
    Pfankuchen DB; Stölting DP; Schlesinger M; Royer HD; Bendas G
    Biochem Pharmacol; 2015 Sep; 97(2):147-57. PubMed ID: 26239805
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinicopathological correlates of hyperparathyroidism.
    Duan K; Gomez Hernandez K; Mete O
    J Clin Pathol; 2015 Oct; 68(10):771-87. PubMed ID: 26163537
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
    Bani MR; Nicoletti MI; Alkharouf NW; Ghilardi C; Petersen D; Erba E; Sausville EA; Liu ET; Giavazzi R
    Mol Cancer Ther; 2004 Feb; 3(2):111-21. PubMed ID: 14985451
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
    Gregory RK; Hill ME; Moore J; A'Hern RP; Johnston SR; Blake P; Shephard J; Barton D; Gore ME
    Eur J Cancer; 2000 Mar; 36(4):503-7. PubMed ID: 10717527
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Primary hyperaldosteronism: our experience with 34 patients].
    Arganini M; Pascucci S; Matteo Cecchini G; Spinelli C; Miccoli P
    Ann Ital Chir; 1990; 61(6):603-6. PubMed ID: 2100107
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.